深圳市银宝山新科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002786 证券简称：银宝山新 公告编号：2025-041 （公告编号：2024-004）、 《关 于向公司关联方借款暨关联交易的进展公告》（公告编号：2024-006、2024-007、 二、进展情况 近日，公司向关联方布拉德归还部分借款人民币 1,740 万元。截至本公告日， 上述关联交易事项借款本金累计金额为人民币 12,760 万元。公司将严格按照《深 圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号— —主板上市公司规范运作》等相关法律法规和规范性文件的规定，及时披露关联 交易的进展情况。 特此公告 深圳市银宝山新科技股份有限公司董事会 一、关联交易概述 深圳市银宝山新科技股份有限公司（以下简称"公司"）于 2024 年 1 月 8 日 召开 2024 年第一次临时股东大会，审议通过了《关于向公司关联方借款暨关联交 易的议案》。公司向淮安布拉德投资发展有限公司（以下简称"布拉德"）申请借 款，借款金额不超过人民币 15,000 万元。具 ...

Overview of the Transaction - The company approved a total guarantee amount of RMB 136,935 million for its wholly-owned and controlling subsidiaries during meetings held on April 24, 2025, and May 20, 2025 [2] - The controlling subsidiary, Hunan Bobang Shanhe New Materials Co., Ltd., plans to apply for a financing lease project loan from Shanghai Wanbao [2] Details of the Guarantee - The company signed a guarantee contract with Shanghai Wanbao on May 28, 2025, to provide a joint liability guarantee for a loan of RMB 30 million, covering 34% of the total debt [5][10] - The subsidiary Zhongji Shanhe also signed a guarantee contract for the same loan, covering 15% of the total debt [5][10] - After this guarantee, the remaining available guarantee amount for Bobang Shanhe is RMB 13,530 million [5] Related Party Transaction - The transaction constitutes a related party transaction as Shanghai Wanbao is a subsidiary controlled by the ultimate controlling party of the company [4] Financial Metrics of the Parties Involved - Bobang Shanhe has a registered capital of RMB 17,000 million and is not listed as a dishonest executor [8] - Shanghai Wanbao has a registered capital of RMB 50,000 million and engages in financial leasing, commercial factoring, asset management, and financing guarantees [9] Previous Transactions and Approvals - As of April 30, 2025, the company and its subsidiaries had conducted financing lease transactions with Shanghai Wanbao totaling RMB 10,870.09 million [12] - The annual shareholders' meeting approved an estimated transaction amount of RMB 70,000 million for 2025 with Shanghai Wanbao [12] Board Approval and Compliance - The guarantee matter has been approved by the company's board and the annual shareholders' meeting, ensuring compliance with fair pricing principles [12]

Core Viewpoint - Company *ST Lvkang plans to sell its photovoltaic film business assets and liabilities to a newly established entity, Jiangxi Raoxin New Energy Materials Co., Ltd, with a registered capital of RMB 100 million [2][3] Group 1: Transaction Details - The transaction involves the sale of assets and liabilities related to the photovoltaic film business, and after completion, the related subsidiaries will no longer be included in the company's consolidated financial statements [3] - The major shareholder of Jiangxi Raoxin is Shanghai Kangyi Investment Co., Ltd, holding 58.63% of the shares, while other significant shareholders include Hangzhou Yirui Investment Partnership and Hangzhou Haoying Investment Partnership, each holding 16.55% [3] - The transaction will be conducted in cash and will not affect the company's shareholding structure [3] Group 2: Financial Overview - In 2024, the revenue from the photovoltaic film business is projected to be RMB 231 million, representing a year-on-year increase of 60.89%, accounting for 35.62% of total revenue [5] - The gross profit margin for the photovoltaic film business in 2024 is expected to be -38.63, contributing to increased losses for the company [5] - From 2021 to 2024, the company's revenue figures were RMB 363 million, RMB 330 million, RMB 507 million, and RMB 649 million, with net losses totaling RMB 815 million over the four years [5]

Core Points - The document outlines the operational guidelines for the General Manager of Lianyun Technology (Hangzhou) Co., Ltd, emphasizing the importance of institutionalized, standardized, and scientific management to ensure effective decision-making and operational efficiency [1] Chapter 1: General Principles - The General Manager is responsible for daily business operations and management, reporting to the Board of Directors [1] - The General Manager must adhere to principles of integrity, diligence, legality, and efficiency [1] Chapter 2: Responsibilities and Authority of the General Manager - The General Manager oversees all company management affairs and is accountable to the Board of Directors [2] - Specific powers include organizing the implementation of annual business plans, proposing internal management structures, and determining employee compensation and welfare systems [2][6] - The General Manager can propose the appointment or dismissal of senior management personnel, including Vice General Managers and financial officers [2][6] Chapter 3: General Manager's Office Meetings - The General Manager's office meetings serve as a platform for management personnel to exchange information and make decisions [7] - Meetings can be called as needed, and minutes must be recorded and stored properly [7][8] Chapter 4: Supplementary Provisions - The document stipulates that any matters not covered will follow applicable laws, regulations, and the company's articles of association [8] - The document will take effect upon approval by the Board of Directors and will be subject to modification as necessary [8]

Meeting Overview - The sixth session of the Supervisory Board of China International Airlines Co., Ltd. was held on May 28, 2025, via written proposals, with all five supervisors present, confirming the legality and validity of the meeting [1][2]. Resolutions Passed - The Supervisory Board approved a proposal regarding the continuation of related party transactions with China National Aviation Holding Company, with a voting result of 2 in favor, 0 against, and 3 abstentions. This proposal will be submitted to the shareholders' meeting for approval by non-related shareholders [1][2]. - The Supervisory Board also approved a proposal for a new framework agreement with Cathay Pacific Airways Limited, with unanimous support (5 votes in favor). This proposal will also be submitted to the shareholders' meeting for approval by non-related shareholders [2].

Group 1 - The core point of the news is the change in the indirect controlling shareholder of Bluestar Medical, with Langhui Petrochemical acquiring a 52.0395% stake, diluting Bluestar Group's stake from 98% to 47.0013% [1] - The company emphasizes that this equity change does not trigger a mandatory takeover, nor does it lead to a change in the controlling shareholder or actual controller, and it will not adversely affect the company's business structure or financial status [1][2] - Langhui Petrochemical, previously a subsidiary of Bluestar Medical, has maintained a close cooperative relationship with the company, being its largest supplier for three consecutive years from 2022 to 2024 [2][3] Group 2 - Langhui Petrochemical initiated its listing guidance in September 2021, with the latest guidance period set from January 1 to March 31, 2025, but faces challenges in internal control and independent director appointments [3] - Bluestar Medical has experienced continuous pressure on its performance over the past three years, with revenues of 4.9 billion, 4.93 billion, and 6.25 billion from 2022 to 2024, and net profits of -372 million, -568 million, and -445 million during the same period [4] - As of May 28, Bluestar Investment holds 235 million shares of Bluestar Medical, accounting for 23.31%, with 183 million shares pledged, representing 18.2% of the total share capital [4]

Core Points - The company is holding a second extraordinary general meeting of shareholders in June 2025 to discuss several key proposals [1][8] - The meeting will ensure the rights of shareholders and maintain order, with specific rules for attendance and participation [2][4] Proposal Summaries - Proposal 1: The company plans to sign a licensing agreement with its affiliates and Pfizer Inc. for a dual-targeting antibody product, granting exclusive rights for development and commercialization outside mainland China [4][6] - Proposal 2: A supplementary agreement regarding the distribution of payments from Pfizer under the licensing agreement will be established, with a proposed distribution ratio of 30% for the company and 70% for its affiliate [6][7] - Proposal 3: The company intends to temporarily use surplus funds of 66.6282 million yuan from various projects to supplement working capital and adjust the investment amounts for specific projects, reducing one project’s funding from 400 million yuan to 320 million yuan and increasing another from 610 million yuan to 690 million yuan [7][8]

Core Viewpoint - The controlling shareholder of Sanyou Chemical plans to invest 100 million yuan in its subsidiary, Tangshan Sanyou Silicon Industry, to enhance its financial strength and support future development needs [1] Group 1: Investment Details - The investment amount is set at 100 million yuan, which will be used to increase the capital of the subsidiary [1] - The capital increase has been approved by the company's independent directors and board of directors, and does not require shareholder meeting approval [1] - The investment price is based on an assessed value, ensuring fair transaction pricing without harming the interests of the company and its shareholders [1] Group 2: Strategic Implications - The capital increase is expected to strengthen the financial position of Tangshan Sanyou Silicon Industry, optimizing its capital structure and enhancing its core competitiveness [1] - This move is also aimed at achieving strategic synergy between the company and its shareholders, promoting the healthy development of the subsidiary [1]

Group 1 - The company has signed a new consulting agreement with Dr. Xiaodong Wang, which is a continuation of the previous agreement, effective from May 27, 2025, for a period of three years [1][2] - Under the new agreement, Dr. Wang will receive an annual fixed consulting fee of $100,000, with the possibility of additional discretionary compensation, including a potential bonus of $150,000 [1][2] - The consulting services provided by Dr. Wang will include scientific knowledge and proprietary technology consulting, facilitating communication with academic and investment communities, assisting in recruitment, and promoting business development with other pharmaceutical and biotech companies [1][2] Group 2 - Dr. Wang has significant experience in the pharmaceutical and biotechnology industry, which is expected to contribute positively to the company's development and strategic goals [2] - The continuation of the consulting relationship with Dr. Wang is aligned with the company's strategic and sustainable development needs, benefiting both the company and its shareholders [2]

证券代码：002079 证券简称：苏州固锝 公告编号：2025-026 苏州固锝电子股份有限公司 关于对外投资暨与关联方共同投资的关联交易公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、对外投资暨关联交易概述 苏州固锝电子股份有限公司（以下简称"公司"或"苏州固锝"）和昆山双睿启航创业 投资合伙企业（有限合伙）（以下简称"昆山双睿"）投资共计2,000万元认购中晶微电（上 海）半导体有限公司（以下简称"中晶微电"或"标的公司"）新增注册资本61.8776万元。 其中，苏州固锝投资1,000万元认购上述新增注册资本中的30.9388万元，对应本次增资后中 晶微电2.5316%的股权。 苏州汇明创芯创业投资合伙企业（有限合伙）（以下简称"汇明创芯"或"苏州汇明"） 持有中晶微电3.15%的股权，苏州固锝为汇明创芯的有限合伙人持有其45.45%的份额，苏州 固锝与汇明创芯构成关联方，本次投资事项构成与关联方共同投资。 事会审批权限范围内，无需提交股东大会审议。本次关联交易不构成《上市公司重大资产重 组管理办法》规定的重大资产重组，无需经过有关部门批准。 二 ...